ArticleAlimentary pharmacology & therapeutics2022
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.
Article in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.Alimentary pharmacology & therapeutics · 2026Article
- Epidemiology of Meal-Related Abdominal Discomfort or Pain in Irritable Bowel Syndrome.Neurogastroenterology and motility · 2025Article
- Common misconceptions and controversies in the management of irritable bowel syndrome.Nature reviews. Gastroenterology & hepatology · 2025Review
- The synthesis of the psychosocial and the physiological aspects of chronic digestive disease is at a crossroads.Translational gastroenterology and hepatology · 2025Article
- Treating disorders of brain-gut interaction with multidisciplinary integrated care. Moving towards a new standard of care.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome.Neurogastroenterology and motility · 2023Article
- Patient satisfaction after remotely delivered gut-directed hypnotherapy for irritable bowel syndrome during the COVID-19 era: implications for future practice.BMJ open gastroenterology · 2022Article
- Impact of Rome IV irritable bowel syndrome on work and activities of daily living.Alimentary pharmacology & therapeutics · 2022Article
- Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.Alimentary pharmacology & therapeutics · 2022Article
- Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome drugs for irritable bowel syndrome (IBS) have serious side effects.
aimsTo examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure.
methodsWe collected demographic, gastrointestinal symptoms, psychological health, quality of life and impact on work and daily activities data from 752 adults with Rome IV-defined IBS. We examined median willingness to accept death in return for cure with a hypothetical medication using a standard gamble, according to these variables.
resultsParticipants would accept a median 2.0% (IQR 0.0%-9.0%) risk of death in return for a 98.0% (IQR 91.0%-100.0%) chance of permanent symptom cure. The median accepted risk of death was higher in men (5.0% vs 2.0%, P < 0.001), those with continuous abdominal pain (4.0% vs 1.0%, P < 0.001), more severe symptoms (P = 0.005 for trend), abnormal depression scores (P < 0.001 for trend), higher gastrointestinal symptom-specific anxiety (P < 0.001 for trend), and lower IBS-related quality of life (P < 0.001 for trend). Those willing to accept above median risk of death were more likely to be male (17.1% vs 9.1%, P < 0.001), take higher levels of risks in their daily life (P = 0.008 for trend), and report continuous abdominal pain (53.1% vs 39.4%, P < 0.001), and had higher depression (P = 0.004 for trend) and lower quality of life (P < 0.001 for trend) scores.
conclusionPatients are willing to accept significant risks in return for cure of their IBS symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.